Borsa Haberleri
Son finansal haberler · Güncellendi Tem 24, 2026
Poet Technologies Bugün Düştü -- Hisse Şimdi Alınır mı?
Poet Technologies Sank Today -- Is The Stock a Buy Right Now?
Panelists generally agree that POET Technologies is heavily reliant on the Lumilens deal for success, but they have significant concerns …
Alumis Hissesi Yüzde 300'den Fazla Yükseldi. Büyük Bir Sağlık Yatırımcısı Kesinti Yapıyor
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
The panel consensus is that Omega Fund Management's sale of ALMS shares is likely a rebalancing act rather than a …
Kestra Medical Gelirlerini %63 Artırdı. Bir Fon Hala 351.000 Hissesi Kesti
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Panelists agree that Kestra Medical's cash burn rate is a significant concern, with the company having around 18-20 months of …
Bu Fonun Aslan Stüdyolaruna Yönelik Daha Büyük Bahsi 85 Stok Artışı Arasında Bilmeniz Gerekenler
What to Know About This Fund’s Bigger Bet on Lionsgate Studios Amid an 85% Stock Surge
The panel is divided on Lionsgate's future, with some seeing it as a potential takeover target due to its content …
Neden Bu "Sıkıcı" Hisse Senedi Şu Anda Güçlü Bir Alım
Why This "Boring" Stock Is a Strong Buy Right Now
The panel's net takeaway is that Coca-Cola's current valuation (24x forward P/E) leaves little room for margin compression, and its …
Neden Charles Schwab Hissesi Cuma Günü Yükseldi?
Why Charles Schwab Stock Bumped Higher on Friday
Panelists are neutral on Schwab, citing rate sensitivity and structural risks, while acknowledging potential ROE improvement from deposit normalization.
Bu Teknoloji Aksi Para Yaratmış Yatkın Yatırmanlar için 5 Yıl, ve Hemen Çok Yaşamlı
This Tech Stock Has Printed Money for Patient Investors for 5 Years, and It's Still Cheap
Onto Innovation's growth prospects hinge on the successful ramp of the Dragonfly G5 platform and maintaining its large HBM backlog. …
Bu Seyahat Aksi Sürücü 38% Yükselişte, Ama Bir Fond 24 Milyon Dolar Artırıldı
This Travel Stock Is Down 38%, but a Fund Just Increased Its Position by $24 Million
The panel generally expresses skepticism about TRIP's turnaround prospects, with concerns about the core hotel business's decay, lack of operating …
'Borçlu Olmadığım 20.000 £'yi Aldılar': Ebeveynler Çocuk Bakım Hatalarından Etkilendi
'They took £20,000 I didn't owe': Parents hit by child maintenance errors
The panel agrees that the Child Maintenance Service's (CMS) high appeal overturn rate and lack of transparency regarding the monetary …
Tahmin: Bu Hisseler 2031'e Kadar İkiye Katlanabilir
Prediction: This Stock Could Double By 2031
Panelists agreed that Exelixis' valuation hinges on the success of zanzalintinib, with significant risks around its late-stage trials and patent …
Elon Musk ve OpenAI avukatları, yapay zekanın geleceğini şekillendirebilecek bir davada son argümanlarını sundu
Lawyers for Elon Musk and OpenAI make their final case in a trial that could shape AI's future
The panel consensus is that the trial's outcome, while important, may not be the most significant risk factor for OpenAI's …
Bicara Hissesi %50 Yükseldi ve Bir Biyoteknoloji Yatırımcısı Portföyünün %29'unu Bu Hisselere Yatırmış Durumda
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Omega Fund's 29% allocation to Bicara (BCAX) reflects high conviction in ficerafusp alfa's Phase 2/3 trial, but the extreme concentration …